NCT00407303View on ClinicalTrials.gov

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

November 30, 2009

Conditions
Mantle-Cell Lymphoma
Interventions
DRUG

Obatoclax mesylate

30 mg, 45 mg

DRUG

Bortezomib

1.0mg/m2, 1.3 mg/m2

Trial Locations (5)

14263

Roswell Park Medical Center, Buffalo

30060

NW Georgia Oncology Centers, Marietta

53792

University of Wisconsin, Madison

60611

Northwestern University Feinberg School of Medicine, Chicago

07601

Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

Gemin X
All Listed Sponsors
lead

Gemin X

INDUSTRY

NCT00407303 - Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Biotech Hunter | Biotech Hunter